EP 2838562 B1 20170830 - HUMAN ANTIBODIES AND SPECIFIC BINDING SEQUENCES THEREOF FOR USE IN STROKE AND ISCHEMIA OR ISCHEMIC CONDITIONS
Title (en)
HUMAN ANTIBODIES AND SPECIFIC BINDING SEQUENCES THEREOF FOR USE IN STROKE AND ISCHEMIA OR ISCHEMIC CONDITIONS
Title (de)
MENSCHLICHE ANTIKÖRPER UND SPEZIFISCHE BINDUNGSSEQUENZEN DAVON ZUR VERWENDUNG BEI APOPLEXIE UND ISCHÄMIE ODER ISCHÄMISCHEN ZUSTÄNDEN
Title (fr)
ANTICORPS HUMAINS ET SÉQUENCES DE LIAISON SPÉCIFIQUES DE CEUX-CI À UTILISER POUR UN ACCIDENT VASCULAIRE CÉRÉBRAL ET UNE ISCHÉMIE OU DES ÉTATS ISCHÉMIQUES
Publication
Application
Priority
- US 201261625628 P 20120417
- US 2013036947 W 20130417
Abstract (en)
[origin: WO2013158748A1] Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease, and in particular in the treatment or alleviation of stroke or cerebral ischemia. The antibodies, variable regions or CDR domain sequences. thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. The antibodies or active fragments thereof may be used in therapy for stroke or cerebral ischemia alone or in combination with thrombolytics such as TPA. Antibodies are exemplified by the antibodies lgM12 and lgM42 whose sequences are provided herein.
IPC 8 full level
A61K 39/395 (2006.01)
CPC (source: EP IL US)
A61K 39/39541 (2013.01 - IL US); A61K 45/06 (2013.01 - IL US); A61K 51/1018 (2013.01 - IL US); A61P 3/06 (2018.01 - EP); A61P 7/02 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/12 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 16/06 (2013.01 - EP IL US); C07K 16/18 (2013.01 - EP IL US); A61K 2039/505 (2013.01 - EP IL US); A61K 2039/507 (2013.01 - EP IL US); A61K 2039/545 (2013.01 - EP IL US); A61K 2039/55 (2013.01 - IL US); C07K 2317/21 (2013.01 - EP IL US); C07K 2317/24 (2013.01 - IL US); C07K 2317/52 (2013.01 - IL US); C07K 2317/565 (2013.01 - IL US); C07K 2317/92 (2013.01 - EP IL US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2013158748 A1 20131024; BR 112014025898 A2 20171107; CA 2870625 A1 20131024; CA 2870625 C 20230620; CN 104379167 A 20150225; CN 104379167 B 20180213; CN 108285483 A 20180717; CN 108285483 B 20220426; EP 2838562 A1 20150225; EP 2838562 A4 20150930; EP 2838562 B1 20170830; EP 3305323 A1 20180411; EP 3305323 B1 20210217; ES 2655077 T3 20180216; ES 2870717 T3 20211027; HK 1206997 A1 20160122; HK 1207565 A1 20160205; HK 1258380 A1 20191108; IL 235118 A0 20141231; IL 235118 B 20190630; IL 266658 A 20190731; IL 266658 B 20210429; IN 2274MUN2014 A 20150807; JP 2015520608 A 20150723; JP 2017127329 A 20170727; JP 2019050832 A 20190404; JP 2021000120 A 20210107; JP 2022107016 A 20220720; JP 6162219 B2 20170712; MX 2014012651 A 20150507; MX 356347 B 20180523; NZ 701278 A 20161223; US 2015104460 A1 20150416
DOCDB simple family (application)
US 2013036947 W 20130417; BR 112014025898 A 20130417; CA 2870625 A 20130417; CN 201380027368 A 20130417; CN 201810021751 A 20130417; EP 13778780 A 20130417; EP 17188389 A 20130417; ES 13778780 T 20130417; ES 17188389 T 20130417; HK 15107727 A 20150811; HK 15108177 A 20150824; HK 19100777 A 20190117; IL 23511814 A 20141019; IL 26665819 A 20190515; IN 2274MUN2014 A 20141111; JP 2015507147 A 20130417; JP 2017089783 A 20170428; JP 2019000205 A 20190104; JP 2020158408 A 20200923; JP 2022080204 A 20220516; MX 2014012651 A 20130417; NZ 70127813 A 20130417; US 201314395141 A 20130417